Eunice L. Kwak

TL;DR: The efficacy of afatinib, an irreversible ErbB Family Blocker, was evaluated in patients who had 1 of 4 categories of solid tumors with epidermal growth factor receptor/human epiderm growth factor receptors (EGFR/HER2) gene amplification or EGFR‐activating mutations.

TL;DR: The first-in-human phase 1 trial examined the dose-limiting toxicities, maximum tolerated dose (MTD), pharmacokinetic profile, and antitumor activity of TLC388, a novel camptothecin with a unique lactone ring modification, in patients with advanced solid tumors, finding it generally safe and well tolerated.

TL;DR: RO4929097 (R) is a potent, selective oral inhibitor of gamma-secretase, a key enzyme in Notch activation, which is implicated in many human cancers.

TL;DR: IMO-2055 combined with FOLFIRI/cetuximab was well tolerated at all dose levels tested and the most common adverse events were injection site reactions, diarrhea, fatigue, hypomagnesemia, and stomatitis.

TL;DR: Clinical improvement and rapid radiographic regression in a MET-amplified GBM patient treated with crizotinib, a dual MET/ALK inhibitor, suggests MET may be a rational target in GBM, even for patients who progress on anti-angiogenic therapy.